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A B S T R A C T
Introduction: The use of second-generation atypical antipsychotics has an increasing role in the
development of metabolic syndrome. However, these medications due to metabolic disorders can lead to
an increased risk of cardiovascular disease and subsequently mortality as well as reduced adherence to
treatment. The main objective of current study was to determine the ability of melatonin to reduce the
metabolic effects of second-generation antipsychotics.
Methods: This double blind controlled clinical trial was conducted on 100 patients aged 18–64 years old
were treated with the second-generation antipsychotics for the ﬁrst time. The patients were divided
randomly into two groups of 50. The case group received slow-release melatonin at a dose of 3 mg and the
control group was given oral placebo at 8 p.m.
Results: The ﬁndings in melatonin group indicated signiﬁcantly increase of HDL and decreased fasting
blood sugar and systolic blood pressure, as well as had statistically signiﬁcant increase in waist
circumference, weight and BMI compared with placebo group.
Conclusion: According to the ﬁndings, it can be claimed that the addition of melatonin to atypical
antipsychotics has led to a reduction in some of the metabolic effects of these drugs. In this study, HDL
level was increased, and the mean systolic blood pressure and FBS were decreased in the melatonin
group. Considering that these factors are contributing to cardiovascular disease as a leading cause of
mortality in psychiatric patients, so the use of melatonin can reduce some of the medical effects of long-
term treatment of atypical antipsychotics.
© 2017 Diabetes India. Published by Elsevier Ltd. All rights reserved.
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The second-generation antipsychotics (SGAs) are a group of
medications introduced to clinical psychiatry in the early 1990s.
The SGAs are currently the most prescribed drugs for schizophre-
nia and other psychosis-related illnesses in most parts of the
world. These drugs are also called SDAs (serotonin-dopamine
antagonists) due to the high afﬁnity for D2 and 5-HT2A receptors
[1].
Clozapine was the ﬁrst drug introduced in 1990 in the United
States, although it has been available since the early 1970s in some
European countries. The clozapine is known as the atypical* Corresponding author at: Department of Psychiatry, Kashan University of
Medical Sciences, Kashan, Iran.
E-mail address: chpharmacy@gmail.com (F. Izadpanah).
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1871-4021/© 2017 Diabetes India. Published by Elsevier Ltd. All rights reserved.antipsychotics due to negligible extrapyramidal side effects. In
addition, it is effective in a group of mood and anxiety symptoms
that are common in schizophrenia. Following the clozapine, other
drugs with fewer side effects were released to the market,
including risperidone, olanzapine, quetiapine, ziprasidone and
aripiprazole [1].
All SGAs are recommended for the treatment of schizophrenia,
most of them are suitable for monotherapy or supportive therapy
in bipolar disorder, and some have been conﬁrmed for the
treatment of major depression [2].
The ﬁrst-generation antipsychotics are the D2 receptor
antagonists, while the second-generation antipsychotics are the
antagonists of D2 and serotonin receptors [3,4]. The use of ﬁrst-
generation antipsychotics has been limited due to severe and
intolerable complications, especially in the elderly [5]. The use of
second-generation antipsychotics is on the rise among elderly
people around the world. The use of these drugs has been
Table 1
Frequency distribution of descriptive variables in the studied groups.
Variables Groups P value*
Melatonin Placebo
Gender Male 22 (44%) 29 (58%) 0.161
Female 28 (56%) 21 (42%)
Total 50 50
Educational level Illiterate 3 (6%) 5 (10%) 0.21
Primary school 15 (30%) 16 (32%)
Secondary school 18 (36%) 8 (16%)
High school 9 (18%) 15 (30%)
Academic 5 (10%) 6 (12%)
Total 50 50
marital status Single 18 (36%) 18 (36%) 0.897
Married 30 (60%) 29 (58%)
Deceased spouse 2 (4%) 3 (6%)
Total 50 50
Age (year) 29 11 (22%) 15 (30%) 0.36
30–34 25 (50%) 18 (36%)
45 14 (28%) 17 (34%)
sdx 37.4  10.3 37.46  12.42 0.986
* P value: signiﬁcance level related to the used test “Chi”.
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and the possibility of sudden death [6]. These drugs are also
increasingly applied in adolescents, and their administration rates
have increased signiﬁcantly [7].
People with mental illness, such as bipolar disorder and
schizophrenia, are more likely to be exposed to metabolic
disorders such as obesity, hypertension, diabetes, and lipid
disorders; for example, obesity among them is 1.5–5 times more
prevalent compared to the general population [8].
Although the second-generation antipsychotics have proven
effects on the acute and long-term treatment of these disorders,
and are the ﬁrst choice of treatment, but unfortunately in turn
cause weight gain [9]. Numerous studies have demonstrated an
association between these medications and increased triglycerides
[10]. An increasing incidence of metabolic syndrome has been
reported because of using the atypical antipsychotics [11]. Three or
more of the following symptoms characterize the metabolic
syndrome: increased waist circumference, increased triglycerides,
decreased HDL, hypertension and high FBS [12]. Among these
drugs, the olanzapine and clozapine have the highest risk of
developing metabolic syndrome [13]. However, these medications
due to metabolic disorders can lead to an increased risk of
cardiovascular disease and subsequently mortality, as well as
reduced adherence to treatment [1].
Various studies have been conducted to reduce these metabolic
complications; for example, the addition of melatonin (N-acetyl-5-
methoxytryptamine) to the therapeutic regimen of patients. This
hormone is secreted in the pineal gland, whose effect is well
known to regulate circadian rhythm of sleep and wakefulness
[14,15]. The hormone secretion is stimulated by darkness and
inhibited by light. Maximum secretion of the melatonin hormone
occurs at 2am, so that is sometimes called “the hormone of
darkness” [16]. Its synthesis is controlled by light under the body
circadian clock located in the suprachiasmatic nucleus [17]. The
melatonin is synthesized from the amino acid precursor “trypto-
phan”, which initially converts into serotonin and eventually into
the melatonin [18]. Exogenous melatonin reportedly ameliorates
the disturbances of the sleep and wakefulness rhythm [19]. The
melatonin also affects basic metabolism, oxidative stress, inﬂam-
mation, apoptosis [20,21], cognitive behavior [22], mood and
behavior [23], and the regulation of metabolic processes such as
insulin, leptin and lipid [24]. The beneﬁcial metabolic effects of
melatonin were ﬁrst shown in mice, in which the administration of
exogenous melatonin prevented the increase in visceral fat, insulin
and leptin in the aging process [25]. The animal model suggests
that melatonin, regardless of food intake and total body fat,
reduces weight gain as well as increases the leukomotor activity
[26].
In a randomized double blind placebo control study conducted
by Francisco Romo-Nava et al. on 20 patients with bipolar disorder
and 24 patients with schizophrenia, the patients were divided into
two groups of 24 (control) and 20 (melatonin) and were studied for
8 weeks. In the melatonin group, there was a decrease in diastolic
blood pressure and weight gain compared to the control group
[27].
As well, Koziróg et al. in 2011 in Netherlands studied 33 healthy
volunteers and 30 patients with metabolic syndrome who were
not treated with lifestyle interventions for 3 months. In this study,
the subjects with metabolic syndrome were prescribed daily 5 mg/
day melatonin two hours before bedtime. Signiﬁcant changes
occurred in systolic blood pressure, diastolic blood pressure, LDL
and antioxidant defense two months after treatment compared to
the baseline. It was found that melatonin might be effective in
treating people with metabolic syndrome [28].
Due to the limited studies carried out and pivotal need for the
therapeutic regimen to reduce or prevent the metabolic effects ofsecond-generation antipsychotics, the main objective of this study
was to determine the ability of melatonin to ameliorate the
metabolic effects of second-generation antipsychotics.
2. Materials and methods
This double blind controlled clinical trial was conducted for
eight weeks on the patients aged 18–64 years old who were
referred as outpatients or hospitalized in Karegarnejad Hospital in
Kashan (Iran) in 2014–2015 and were recently treated with the
second-generation antipsychotics. Exclusion criteria were hyper-
tension, diabetes, lipid disorders, thyroid dysfunction, liver
diseases, history of melatonin allergy, pregnancy, lactation and
history of drug dependence or abuse in the last 6 months. After
explaining the research objectives, possible complications and
related issues to the patient or caregivers, written consent was
obtained from all patients and their relatives.
The patients were randomly assigned to two groups by blocked
randomization procedures. The case group received slow-release
melatonin at a dose of 3 mg and the control group was given oral
placebo at 8 pm. According to the study, in order to compare the
effect of melatonin and placebo on the reduction of metabolic
complications of second-generation antipsychotics, the mean
change in diastolic blood pressure after treatment was
4.6  5.9 in the melatonin group and 1.8  5.8 in the placebo
group.
In terms of LDL, these two measures were 18.6  19.5 and
1.6  21.4, respectively. With regard to 95% conﬁdence interval and
90% test power, the minimum sample size was calculated to be 30
in each group. Considering other measured parameters, this study
was performed on two groups of 50.
The change in the type of antipsychotics was prohibited, but the
dose adjustment was allowed and recorded. The second-genera-
tion antipsychotics are divided into two groups of high-risk
(olanzapine and clozapine) and low-risk (risperidone and quetia-
pine) in terms of the development of metabolic complications.
Other prescription drugs, such as antidepressants, hypnotics and
mood stabilizers are allowed in the presence of clinical indications.
The choice of antipsychotic type was introduced as a confounding
variable, and in case of dose change in each drug, they were
compared to a single criterion. If there was any change in blood
lipids, sugar and pressure proﬁles (possible side effects), these
patients were treated routinely for these parameters in spite of
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study as an outcome variable (Table 1).
The patients were requested to be fasting for 12 h before each
assessment. At ﬁrst, laboratory tests and then the measurements of
weight, height and body mass index were performed, as well as
waist circumference and blood pressures were measured. These
evaluations were performed at baseline, fourth week of treatment
and end of treatment.
Moreover, the patients were asked to maintain constant diet
during treatment, but it was introduced into study as a
confounding factor in case of the changes in physical activity
(Table 2).
2.1. Statistical analysis
Data was analyzed in SPSS software (version 21) using
Kolmogorov-Smirnov test to evaluate the normality of data,
calculating the mean and standard deviation for metabolic
disturbances, and determining the trend of changes during
treatment in the two groups [29–34].
Chi-square test was applied to study the descriptive variables of
the research (gender, age, education and marital status) in two
groups. Independent t-test and repeated measures ANOVA were
exploited to examine the differences between the existing
variables (triglyceride, HDL, cholesterol, FBS, diastolic blood
pressure, systolic blood pressure, waist circumference, weight
and BMI) between the two groups along with the effect of time
[35–42].
In this study, the p value or signiﬁcance level (test error value)
was considered to be 0.05 with 95% conﬁdence interval [43–49].
3. Results
In this study, 100 patients taking atypical antipsychotics
(olanzapine, clozapine, risperidone and quetiapine) were studied
for complications of metabolic syndrome (50 in the melatonin
group and 50 in the placebo group), including 51 males and 49
females. All patients were in the age range of 18–64 years with the
mean age of 37.4 11.35 years. The highest frequency was related
to the age group of 30–45 years, 36% in the melatonin group and
50% in the placebo group.
The males and females were 44% and 56% in the melatonin
group, as well as 58% and 42% in the placebo group, respectively. No
signiﬁcant correlation was found between the treatment groupsTable 2
Mean and standard deviation of variables in the two groups after four and eight week
Variables G
M
Triglyceride Four weeks after treatment 23
Eight weeks after treatment 16
HDL Four weeks after treatment 2.
Eight weeks after treatment 3.
Cholesterol Four weeks after treatment 13
Eight weeks after treatment 11
FBS Four weeks after treatment 2.
Eight weeks after treatment 
Diastolic blood pressure Four weeks after treatment 0.
Eight weeks after treatment 
Systolic blood pressure Four weeks after treatment 
Eight weeks after treatment 
Waist circumference Four weeks after treatment 1.
Eight weeks after treatment 1.
Weight Four weeks after treatment 0.
Eight weeks after treatment 1.
BMI Four weeks after treatment 2.
Eight weeks after treatment 2.with the gender of the patients (P = 0.161). In addition, the highest
frequency was in the educational level of primary school in the
melatonin group, and secondary school in the placebo group. There
was no signiﬁcant relationship between the treatment groups and
the educational status of the patients (P = 0.21). Considering the
above table, there was no statistically signiﬁcant relationship
between marital status of patients and treatment groups
(P = 0.897). In the melatonin group, 30% of patients were under
29 years of age, 36% were between 30 and 44 years, and 34% were
over 45 years of age. In the placebo group, 22% were younger than
29 years of age, 50% between 30 and 44 years old and 28% over 45
years of age. There was no statistically signiﬁcant relationship
between age and treatment groups (P = 0.36). Moreover, the mean
age in both groups was 37.46 and 37.4, respectively (P = 0.986).
After four weeks of treatment, the mean triglyceride was
increased by 23.3 units in the melatonin group and 20 units in the
placebo group; this difference was not statistically signiﬁcant
(P = 0.65). This difference was not signiﬁcant after eight weeks of
treatment as well (P = 0.162).
After four weeks of treatment, the mean HDL was increased by 2
units in the melatonin group, and was decreased by 0.32 units in
the placebo group; this difference was statistically signiﬁcant
(P = 0.04). This signiﬁcant difference was observed after eight
weeks of treatment (P = 0.001).
After four weeks of treatment, the mean cholesterol was
increased by 13.2 units in the melatonin group and 8.5 units in the
placebo group; this difference was not statistically signiﬁcant
(P = 0.219). This difference was not also signiﬁcant after eight
weeks of treatment (P = 0.784).
After four weeks of treatment, the mean FBS was increased by
2.2 units in the melatonin group and 0.5 units in the placebo group;
this difference was not statistically signiﬁcant (P = 0.32). The mean
FBS was reduced by 3 units in the melatonin group and was
increased by 1.3 units in the placebo group; this difference was
signiﬁcant (P = 0.002).
After four weeks of treatment, the mean diastolic blood
pressure was increased by 0.4 units in the melatonin group and
0.6 units in the placebo group; this difference was statistically
signiﬁcant (P = 0.9). This signiﬁcant difference was not observed
after eight weeks of treatment (P = 0.112).
After four weeks of treatment, the mean systolic blood pressure
was decreased by 0.1 units in the melatonin group and 1.2 units in
the placebo group; this difference was not statistically signiﬁcant
(P = 0.596). The mean systolic blood pressure was reduced by 1.4s of treatment.
roups P value
elatonin (Mean  SD) Placebo (Mean  SD)
.38  31.80 20.22  38.34 0.655
.32  24.91 23.62  26.89 0.162
0  5.13 0.32  5.98 0.04
34  6.88 1.58  6.94 0.001
.24  20.91 8.5  17.2 0.219
  22.67 9.88  17.72 0.784
24  9.47 0.56  7.29 0.323
3.02  7.08 1.32  6.42 0.002
4  7.87 0.6  7.93 0.900
0.1  7.85 2.30  7.08 0.112
0.1  9.60 1.2  10.99 0.596
1.4  9.03 2.9  10.5 0.031
6  3.28 0.52  1.18 0.031
97  2.96 0.78  1.31 0.011
93  1.2 0.29  0.62 0.001
1  1.11 0.51  0.71 0.003
51  3.11 0.84  1.71 0.001
95  3.07 1.48  2.06 0.006
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placebo group; this difference was signiﬁcant (P = 0.031).
After four weeks of treatment, the mean waist circumference
was increased by 1.6 units in the melatonin group and 0.52 units in
the placebo group; this difference was statistically signiﬁcant
(P = 0.031). This difference was also signiﬁcant after eight weeks of
treatment (P = 0.011).
After four weeks of treatment, the mean BMI was increased by
0.93 units in the melatonin group and 0.29 units in the placebo
group; this difference was statistically signiﬁcant (P = 0.001). This
difference was also signiﬁcant after eight weeks of treatment
(P = 0.003).
After four weeks of treatment, the mean weight was increased
by 2.5 units in the melatonin group and 0.84 units in the placebo
group; this difference was statistically signiﬁcant (P = 0.001). This
difference was also signiﬁcant after eight weeks of treatment
(P = 0.006).
The results of this table show the effect of time on changes in
triglyceride levels in the patients (P = 0.049). However, no
signiﬁcant interaction was observed between treatment groups
and triglyceride changes in the presence of time effect (P = 0.15).
In addition, the ﬁndings in this table indicate that the time was
not effective on changes in HDL in the patients (P = 0.91). However,
the interaction of treatment groups in the presence of time factor
on HDL changes was signiﬁcant (P = 0.001).
On the other hand, the effect of time on cholesterol changes in
the patients was not signiﬁcant (P = 0.704). As well, no signiﬁcant
interaction was observed between treatment groups and choles-
terol changes in the presence of time factor (P = 0.582).
The results of this table indicate that the factor of time was
ineffective on changes in FBS (P = 0.670), but the interaction of
treatment groups was signiﬁcant on changes in FBS in the presence
of time (P = 0.004).
Based on the results of Table 3, the time factor was ineffective
on the diastolic blood pressure changes in the patients (P = 0.754)
and also the interaction of treatment groups and diastolic blood
pressure changes was not signiﬁcant in the presence of time factor
(P = 0.163).
The results of this table show that the time factor was not
effective on changes in systolic blood pressure in the patients
(P = 0.747). However, the interaction of treatment groups and
systolic blood pressure changes was signiﬁcant in the presence of
time factor (P = 0.013).Table 3
One-way ANOVA results to measure the time difference in variables in two groups.
Source of changes Sum of squared errors 
Triglyceride Time 2792.650 
Time  group 1595.667 
HDL Time 85.442 
Time  group 252.834 
Cholesterol Time 111.582 
Time  group 373.634 
FBS Time 25.513 
Time  group 451.898 
Diastolic blood pressure Time 13.781 
Time  group 95.919 
Systolic blood pressure Time 19.371 
Time  group 407.569 
Waist circumference Time 35.428 
Time  group 18.208 
Weight Time 51.338 
Time  group 38.426 
BMI Time 5.743 
Time  group 5.662 The effect of time factor on waist circumference was positive
(P = 0.001). There was also a signiﬁcant correlation between the
treatment groups and waist circumference in the presence of time
factor (P = 0.025).
Additionally, the time factor affects the weight of patients
(P = 0.000). The interaction of treatment groups and the changes in
weight was signiﬁcant in the presence of time factor (P = 0.002).
Finally, the results of this table show the effect of time factor on
BMI changes in the patients (P = 0.001). Furthermore, the interac-
tion of treatment groups and the changes in BMI was signiﬁcant in
the presence of time factor (P = 0.001).
4. Discussion
The present study examined the effect of melatonin supple-
mentation on metabolic complications of second-generation
antipsychotics. The drugs were olanzapine, clozapine, risperidone
and quetiapine. None of the subjects under study, who were newly
treated, was treated with clozapine. In this study, 100 patients aged
16–64 years were divided randomly in two groups of 50. The case
group received the antipsychotics and the melatonin, and the
control group was administered with the placebo. The study
variables were calculated at weeks 4 and 8 and analyzed by SPSS
21. The age and gender were compared in the two groups to ensure
a lack of confounding factors. The melatonin group included 30% of
people younger than 29 years of age, 36% between 30 and 44 years
old and 34% over 45 years of age, while the placebo group consisted
of 22% less than 29 years old, 50% between 30 and 44 years old and
28% over 45 years old.
The melatonin group also had 44% male and 56% female. The
placebo group included 58% male and 42% female. However, there
was no signiﬁcant difference in age and gender in the study groups.
Due to the increased administration of these drugs, there are
concerns about the long-term use of these drugs. Various studies
have shown that the atypical antipsychotics could increase weight,
BMI and some metabolic syndrome components in the patients.
These complications not only are important in terms of general
health due to increased risk of diabetes mellitus, cardiovascular
disease and blood pressure, but also can lead to a lack of patient
adherence for effective treatment. Therefore, proper solutions
should be considered to minimize these adverse effects.
According to the results of studies showing the regulatory role
of melatonin secreted by the pineal gland in the sleep/wakefulnessDegrees
of freedom
Mean squared error F value P value
1.560 1790.108 3.357 0.049
2 797.833 1.918 0.150
1.806 47.306 2.491 0.091
1.806 139.986 7.371 0.001
1.848 60.375 0.328 0.704
1.848 202.167 1.098 0.582
1.727 14.769 0.355 0.670
1.727 261.597 6.286 0.004
1.882 7.333 0.265 0.754
1.882 50.971 1.846 0.163
1.638 11.826 0.223 0.747
1.638 248.826 4.912 0.013
1.540 22.998 8.255 0.001
1.540 11.820 4.243 0.025
1.730 29.683 9.273 0.000
1.730 22.271 6.940 0.002
1.695 3.389 7.638 0.001
1.695 3.341 7.530 0.001
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distribution, it is hypothesized that daily administration of
melatonin may prevent the metabolic effects of these drugs by
regulating the circadian rhythm of the body. Particularly, the
melatonin is a natural substance without any reported toxicity.
In a study conducted in 2007 in the United States on female rats
weighing 240–250 g for 8 weeks, increasing the body weight and
visceral fat in mice may be related to at least to a lesser extent
secondary to reducing the plasma melatonin levels due to the
olanzapine. In this study, concomitant administration of the
melatonin was able to prevent weight gain induced by olanzapine
[50].
In a study in Netherlands (2011), the lipid and blood pressure
proﬁles were declined signiﬁcantly two months after administra-
tion of melatonin in the patients with metabolic syndrome [28].
In our study, the mean triglyceride was increased in the
melatonin group signiﬁcantly after 4 weeks, and was decreased
after 8 weeks compared to the fourth week. In the placebo group,
the mean triglyceride was increased after 4 weeks and was
increased at week 8 as compared to week 4, indicating the effect
of time on triglyceride changes in the patients (P = 0.049).
However, no signiﬁcant interaction was observed between
treatment groups and triglyceride changes in the presence of
time factor (P = 0.15).
In a study in Shafa Hospital in Rasht (Iran) in 2014, 48 patients
with the ﬁrst episode of schizophrenia candidate for treatment
with olanzapine were randomly assigned to two groups. One of the
groups was treated with olanzapine and melatonin, and another
group was treated with olanzapine and placebo for 8 weeks. In the
group receiving concurrent melatonin, an increase in triglyceride
levels was signiﬁcantly less than the placebo group [51],
inconsistent with our study. In a study in 2014 in Rouzbeh
Hospital in Tehran (Iran), 38 teenagers aged 17–11 years with the
ﬁrst episode of bipolar disorder treated with olanzapine and
melatonin or olanzapine and placebo [52], it was found that the
levels of triglyceride did not differ signiﬁcantly between the two
groups after 12 weeks, similar to this study in terms of the level of
changes in triglyceride in the two groups.
In this study, the mean cholesterol level was increased also in
the melatonin and placebo groups at week 8 compared to the
baseline level, but was not signiﬁcant (P = 0.704). Moreover, the
interaction between treatment groups and cholesterol changes
was not signiﬁcant in the presence of time factor (P = 0.582). The
results of this study were in line with the result of the study carried
out in Shafa Hospital of Rasht concerning the cholesterol changes
in the two groups of melatonin and placebo. In the study in the
Roozbeh Hospital, the increased level of cholesterol in the
melatonin group compared with the placebo group was reported
close to signiﬁcant.
In our study, the HDL level was increased in the melatonin
group at weeks 4 and 8, while the decrease in the HDL level was
observed in the placebo group; these changes were signiﬁcant
(P = 0.001). No changes in the HDL level have been mentioned in
other studies. In this study, the mean diastolic blood pressure was
increased in the melatonin group at week 4 and then decreased at
week 8. In the placebo group, the mean diastolic blood pressure
was elevated at weeks 4 and 8; these changes were not signiﬁcant
(P = 0.163). In a study for 8 weeks in Mexico in 2014, 44 patients (20
bipolar patients and 24 schizophrenic patients) were diagnosed
with a reduction in diastolic blood pressure in the melatonin group
[27], no matched with the outcome of this study. However, the
result of this study was similar to the study in the Roozbeh Hospital
and no signiﬁcant changes in diastolic blood pressure were
reported in melatonin and placebo groups.
The mean systolic blood pressure was decreased at weeks 4 and
8 in the melatonin group in this study, but ﬁrstly was decreased atweek 4 in the placebo group and was increased at week 8; these
changes in the mean systolic blood pressure were signiﬁcant
(P = 0.013). The result of this study is consistent with the study in
the Roozbeh Hospital in Tehran.
In our study, the FBS level also was increased in the 4th week of
the melatonin group, but decreased by 8 weeks compared to the
baseline; and was increased in the 4th and 8th weeks in the
placebo group; this difference was statistically signiﬁcant
(P = 0.004). However, this factor showed no signiﬁcant difference
in the study of the Shafa Hospital of Rasht. In addition, the
difference in the FBS level due to melatonin was not signiﬁcantly
higher in the study in the Roozbeh Hospital, as opposed to the
outcome of this study.
In our study, the mean waist circumference was increased in the
melatonin and placebo groups at weeks 4 and 8, but this increase
was higher in the melatonin group, which was statistically
signiﬁcant (P = 0.025). However, the mean changes in waist
circumference in the melatonin group were signiﬁcant in
comparison to the placebo group in the study in the Shafa
Hospital of Rasht.
In this study, the mean weight gain was also increased in both
groups at weeks 4 and 8; this increase was higher in the melatonin
group and was statistically signiﬁcant (P = 0.002). In a study by
Francisco Romo-Nava in Mexico, a decrease was observed in
weight gain in the melatonin group in bipolar patients, and not in
the schizophrenic group [27].
As well, in the study in the Shafa Hospital of Rasht, the
melatonin group had less weight gain than the placebo group,
which was reported signiﬁcantly inconsistent with the results of
this study. In the study in the Roozbeh Hospital, weight gain was
also signiﬁcantly lower in the melatonin group.
Regarding the increased waist circumference and weight gain in
both groups, the BMI was increased in both groups at weeks 4 and 8;
the increase was higher in the melatonin group (P = 0.001). In the
study in the Roozbeh Hospital, the decrease in BMI in the melatonin
group was close to signiﬁcant compared to the placebo group.
Additionally, in a randomized double blind placebo-controlled
study in 2006 on adult female rats, the cases receiving olanzapine
for 35 days showed signiﬁcant weight gain compared to the control
group. Then they were divided into three groups and were
administered 20, 60 or 200 mg/day of Mifepristone (a potent
glucocorticoid antagonist). On day 21, the rats had signiﬁcant
weight loss. The rats taking 200 mg/day had signiﬁcantly less
abdominal fat than the control group [53].
In another study in 2009, 57 men aged 19–38 years had weight
gain and waist circumference signiﬁcantly higher in the group
receiving olanzapine and placebo than those taking the olanzapine
and mifepristone [54].
Deng in 2012 indicated that co-administration of betahitne
with olanzapine reduced the weight gain induced by the
olanzapine [55].
A study was conducted in 2013 on rats regarding the fact that
olanzapine causes a change in the intestinal microﬂora. A group of
rats were given olanzapine + antibiotics (a cocktail of neomycin,
metronidazole, and polymyxin B), and the control group received
olanzapine and placebo. The antibiotic cocktail was shown to cause
weight loss in the rats. Thus, it was hypothesized that the change in
intestinal microﬂora plays a role in metabolic disorders caused by
olanzapine [56].
In a study conducted in 2008, it was observed that adding
metformin for 12 weeks into olanzapine in 40 patients with
schizophrenia, the increase in weight, waist circumference and
BMI was found to be lower n the metformin group than in the
control group [57].
In another double blind study in 2010 for 12 weeks, 72
schizophrenic patients were divided into two groups of
14 M. Agahi et al. / Diabetes & Metabolic Syndrome: Clinical Research & Reviews 12 (2018) 9–15olanzapine + placebo and olanzapine + topiramate (100 mg/day). At
the end of study, it was shown that topiramate can prevent weight
gain resulting from olanzapine and its metabolic effects, as well as
causes a reduction in weight, glucose, cholesterol, triglycerides and
systolic and diastolic blood pressure [58].
In summary, the increase in HDL and the decrease in FBS and
systolic blood pressure were observed signiﬁcantly in the
melatonin group in our study, as well as the elevation in waist
circumference, weight and BMI were statistically signiﬁcant higher
than the placebo group.
5. Conclusion
According to the results obtained from the current research, it
can be concluded that the addition of melatonin to atypical
antipsychotics decreased some of the metabolic effects of these
drugs. In this study, the HDL level was increased, and the mean
systolic blood pressure and FBS were decreased in the melatonin
group. Considering that these factors are contributing to cardio-
vascular disease as a leading cause of mortality in psychiatric
patients, so the use of melatonin can reduce some of the medical
effects of long-term treatment of atypical antipsychotics.
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